<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697265</url>
  </required_header>
  <id_info>
    <org_study_id>UM203</org_study_id>
    <nct_id>NCT03697265</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)</brief_title>
  <official_title>A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study Investigating Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asarina Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ergomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asarina Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this phase IIb study is to evaluate the effect and safety of Sepranolone&#xD;
      (UC1010) on premenstrual symptoms in women with Premenstrual Dysphoric Disorder (PMDD).&#xD;
      Patients will be taking Sepranolone or Placebo (blinded to patient and study doctor) during&#xD;
      the two weeks preceding the menstruation of three menstrual cycles. Effect (change from&#xD;
      baseline) will be assessed by comparison of symptoms recorded daily by the patients using a&#xD;
      validated rating scale for assessment of PMDD symptoms. Sepranolone is an endogenous steroid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this phase IIb study is to evaluate the effect and safety of two doses of&#xD;
      Sepranolone (UC1010) on premenstrual symptoms in women with Premenstrual Dysphoric Disorder&#xD;
      (PMDD) in comparison to placebo, administrated during the luteal phase of three consecutive&#xD;
      menstrual cycles. Effect will be assessed by comparison of symptoms recorded daily by the&#xD;
      patients using a validated rating scale for assessment of PMDD symptoms and impairment of&#xD;
      symptoms on daily life of the patients. The scale is Daily Record of Severity of Problems&#xD;
      (DRSP). Preceding the treatment period, the diagnosis of PMDD will be established in the&#xD;
      study participants by at lest two menstrual cycles of prospective DRSP ratings by the&#xD;
      patients. This period will also constitute the baseline data. The effect of study medication&#xD;
      will be assessed as the change in symptoms from baseline to during treatment. The Total&#xD;
      symptom score of the DRSP will constitute the primary variable and the late luteal phase&#xD;
      ratings in the respective menstrual cycles, before and during treatment, will be used.&#xD;
&#xD;
      The study will also include a follow-up (no treatment) cycle before patients final visit.&#xD;
&#xD;
      The study is conducted in four European countries (Sweden, Germany, Poland and United&#xD;
      Kingdom) and will include up to 225 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Actual">October 23, 2020</completion_date>
  <primary_completion_date type="Actual">July 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on DRSP Total symptom score</measure>
    <time_frame>Baseline luteal phase score (average from two menstrual cycles) vs. luteal phase score during treatment.</time_frame>
    <description>Change in DRSP Total symptom score (Daily Record of Severity of Problems) measured during the luteal phase (i.e. the week before menstruation) before and during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Starting from first dose given until 1 months after treatment stop</time_frame>
    <description>Recording of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">475</enrollment>
  <condition>Premenstrual Dysphoric Disorder</condition>
  <arm_group>
    <arm_group_label>Sepranolone (UC1010) low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sepranolone (UC1010) low dose administered subcutaneously (SC) during the luteal phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepranolone (UC1010) high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sepranolone (UC1010) high dose administered subcutaneously (SC) during the luteal phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously (SC) during the luteal phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sepranolone (UC1010) low dose</intervention_name>
    <description>Subcutaneous (SC) administration</description>
    <arm_group_label>Sepranolone (UC1010) low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sepranolone (UC1010) high dose</intervention_name>
    <description>Subcutaneous (SC) administration</description>
    <arm_group_label>Sepranolone (UC1010) high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous (SC) adminstration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  have PMDD according to DSM-5 verified in two menstrual cycles&#xD;
&#xD;
          -  have a regular menstrual cycle of 24-35 days cycle,&#xD;
&#xD;
          -  use double barrier contraception, non-hormonal IUD, be truly sexually abstinent, or&#xD;
             subject or her partner has been surgically sterilized,&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  steroid hormonal treatment or treatment with psychopharmaceuticals during previous&#xD;
             three months&#xD;
&#xD;
          -  treatments for premenstrual syndrome (PMS) or PMDD&#xD;
&#xD;
          -  history of or significant medical condition ongoing&#xD;
&#xD;
          -  be pregnant or plan a pregnancy within the study period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Woman with regular menstrual cycles</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaughn O'Brien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrics and Gynaecology Keele University School of Medicine and University Hospitals of North Staffordshire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Klinische Forschnung</name>
      <address>
        <city>Bad Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emovis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizentrum Essen Borbeck</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Karlsruhe GmbH</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Steinwachs</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kliniczno-Badawcze</name>
      <address>
        <city>Elbląg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProCreative</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Women's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetrics and Gynaecology Keele University School of Medicine and University Hospitals of North Staffordshire</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017 Jun;80:46-55. doi: 10.1016/j.psyneuen.2017.02.031. Epub 2017 Mar 1.</citation>
    <PMID>28319848</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

